BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that three abstracts highlighting results of its Phase 2, open-label study of NE3107 in patients with Alzheimer’s Disease (AD) were accepted for presentation at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, to be held November 29-December 2, 2022 in San Francisco, CA.
Details of the presentations are as follows:
Oral Presentation:
Neuroimaging Data from a Phase 2, open-label Study of NE3107 in Patients with Cognitive Decline Due to Degenerative Dementias; Kaya Jordan, et al
Friday, December 2 at 11:15am PT
Poster Presentations:
PO95 Biomarker Assessments from a Phase 2, open-label Study of NE3107 in Patients with Cognitive Decline Due to Degenerative Dementias; Jonathan Haroon, et al
Thursday, December 1 8:00am-6:00pm PT
PO34 Clinical Outcomes from a Phase 2, open-label Study of NE3107 in Patients with Cognitive Decline Due to Degenerative Dementias; Elisabeth Rindner, et al
Tuesday, November 29 at 4:00pm PT to Wednesday November 30 at 6:00pm PT
Details of the presented data and conclusions will be announced once the presentations are made public at the conference.
https://www.marketscreener.com/quote/stock/BIOVIE-INC-30558504/news/BioVie-to-Present-Data-from-Investigator-Sponsored-Exploratory-Biomarker-and-Imaging-Trial-of-NE3107-42320530/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.